Literature DB >> 9870399

Analysis of microdialysates from cancer patients by capillary electrophoresis.

R M Mader1, M Brunner, B Rizovski, C Mensik, G G Steger, H G Eichler, M Müller.   

Abstract

Microdialysis (MD) is an innovative clinical technique for measuring interstitial tissue pharmacokinetics and plasma-to-tissue transfer rates of drugs in humans. However, microdialysis requires the availability of specialized analytical techniques. Capillary electrophoresis (CE), which enables concentration measurements of small volume samples, theoretically constitutes an ideal analytical technique for measuring drug concentrations in microdialysates. In the present experiments, we aimed at assessing the potential utility and limitations of CE for analysis of microdialysates in a clinical situation. Microdialysates were obtained from primary breast cancer patients who received chemotherapy including 5-fluorouracil (5-FU; 600 mg/m2). Subsequently, 5-FU concentrations were measured in tumor - and subcutaneous adipose tissue - microdialysates by CE. By combining MD and CE, complete time versus concentrations profiles could be obtained for 5-FU in the interstitial tumor space and important clinical questions could be addressed. We conclude that the combination of MD and CE leads to important and previously inaccessible information about the drug distribution process in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870399     DOI: 10.1002/elps.1150191630

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

1.  Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer.

Authors:  R M Mader; C Schrolnberger; B Rizovski; M Brunner; C Wenzel; G Locker; H G Eichler; M Mueller; G G Steger
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

2.  Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

Authors:  J F Thompson; G A Siebert; Y G Anissimov; B M Smithers; A Doubrovsky; C D Anderson; M S Roberts
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.